Biodesix, Inc. (BDSX)
NASDAQ: BDSX · Real-Time Price · USD
0.5387
-0.0325 (-5.69%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Biodesix Statistics

Total Valuation

Biodesix has a market cap or net worth of $78.68 million. The enterprise value is $115.82 million.

Market Cap 78.68M
Enterprise Value 115.82M

Important Dates

The next estimated earnings date is Wednesday, May 7, 2025, after market close.

Earnings Date May 7, 2025
Ex-Dividend Date n/a

Share Statistics

Biodesix has 145.98 million shares outstanding. The number of shares has increased by 57.92% in one year.

Current Share Class 145.98M
Shares Outstanding 145.98M
Shares Change (YoY) +57.92%
Shares Change (QoQ) +0.21%
Owned by Insiders (%) 47.69%
Owned by Institutions (%) 32.94%
Float 66.18M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.98
Forward PS 0.84
PB Ratio 3.76
P/TBV Ratio n/a
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 1.62
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.76, with a Debt / Equity ratio of 3.04.

Current Ratio 2.76
Quick Ratio 2.43
Debt / Equity 3.04
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -4.15

Financial Efficiency

Return on equity (ROE) is -337.30% and return on invested capital (ROIC) is -28.64%.

Return on Equity (ROE) -337.30%
Return on Assets (ROA) -21.81%
Return on Invested Capital (ROIC) -28.64%
Return on Capital Employed (ROCE) -41.31%
Revenue Per Employee $261,256
Profits Per Employee -$157,256
Employee Count 273
Asset Turnover 0.73
Inventory Turnover 12.98

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -57.25% in the last 52 weeks. The beta is 1.16, so Biodesix's price volatility has been higher than the market average.

Beta (5Y) 1.16
52-Week Price Change -57.25%
50-Day Moving Average 0.72
200-Day Moving Average 1.31
Relative Strength Index (RSI) 40.41
Average Volume (20 Days) 434,877

Short Selling Information

The latest short interest is 1.02 million, so 0.70% of the outstanding shares have been sold short.

Short Interest 1.02M
Short Previous Month 1.16M
Short % of Shares Out 0.70%
Short % of Float 1.54%
Short Ratio (days to cover) 3.23

Income Statement

In the last 12 months, Biodesix had revenue of $71.32 million and -$42.93 million in losses. Loss per share was -$0.33.

Revenue 71.32M
Gross Profit 55.75M
Operating Income -34.26M
Pretax Income n/a
Net Income -42.93M
EBITDA -28.49M
EBIT -34.26M
Loss Per Share -$0.33
Full Income Statement

Balance Sheet

The company has $26.25 million in cash and $63.38 million in debt, giving a net cash position of -$37.14 million or -$0.25 per share.

Cash & Cash Equivalents 26.25M
Total Debt 63.38M
Net Cash -37.14M
Net Cash Per Share -$0.25
Equity (Book Value) 20.88M
Book Value Per Share 0.14
Working Capital 25.17M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$48.65 million and capital expenditures -$3.23 million, giving a free cash flow of -$51.88 million.

Operating Cash Flow -48.65M
Capital Expenditures -3.23M
Free Cash Flow -51.88M
FCF Per Share -$0.36
Full Cash Flow Statement

Margins

Gross margin is 78.17%, with operating and profit margins of -48.04% and -60.19%.

Gross Margin 78.17%
Operating Margin -48.04%
Pretax Margin -60.19%
Profit Margin -60.19%
EBITDA Margin -39.94%
EBIT Margin -48.03%
FCF Margin n/a

Dividends & Yields

Biodesix does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -57.92%
Shareholder Yield n/a
Earnings Yield -54.56%
FCF Yield -65.93%

Analyst Forecast

The average price target for Biodesix is $2.93, which is 443.90% higher than the current price. The consensus rating is "Strong Buy".

Price Target $2.93
Price Target Difference 443.90%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Biodesix has an Altman Z-Score of -5.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -5.2
Piotroski F-Score 3